H. E. M. KAY From the Royal Marsden Hospital, London I hope it is no longer old-fashioned to consider the immune system as being primarily concerned with defence against infection by micro-organisms. I intend to deal with the types of immunodeficiency listed in Table 1 , except for the first two categories, and with particular emphasis on the commonest that we encounter-general immunodeficiency due to metabolic and nutritional abnormalities and druginduced depression of immune activity. We must consider the types of organism concerned, the consequence of an infection during a state of immune suppression, the few specific associations that exist between a particular state of depression and a particular organism, problems in the diagnosis of infection, its prevention, and, very briefly, treatment. Table 3 shows some of the factors that determine whether an infection occurs and the form it takes. Some of these are obvious, such as concomitant tissue damage; others, such as microbial competition, are putative but probably important; and others are considered in more detail below. Table 4 shows some of the consequences of infection in the immunosuppressed-firstly, an over- (Gardner, 1978) .
One must also realise that there is a vicious circle of infection in these susceptible patients. A defective immune system that can react almost normally to a single new agent may be overwhelmed by a double infection especially when, as in the case of measles, there is a strong immunosuppressive effect of the first infection.
When instead of total non-reactivity (which is relatively rare) there is some part of the normal immune response-perhaps, for example, antibodyformation-then there may be pathological consequences-immune complex disease, for example; or atopy if it is a question of the type of antibody produced, IgE rather than G or A; or autoimmunity for which one mechanism might be that the failure of a defective initial response leads to a prolonged production of cross-reacting antibody. In this complex subject some associations are well-documented -for example, the lupus-like syndrome and haemolytic anaemia of the NZB mouse, or the occurrence of arthritis, lupus-like disease, and autoantibodies in patients with immunoglobulin deficiency or in carriers of the gene for chronic granulomatous disease-but the exact chain of cause and effect is not always clear (Soothill, 1976; Schaller, 1975) .
Finally, the failure of an immune response may allow access or proliferation of viruses in the central nervous system. The JC Papova virus, for example, may or may not enter the CNS in normal subjects, but only with severe immunosuppression does it proliferate to cause progressive muftifocal leucoencephalopathy, while 'inclusion-body' measles encephalitis-to be distinguished from acute measles encephalitis and subacute sclerosing panencephalitis (SSPE)-is known only in association with drug treatment (Kay, 1978) .
There are a very few close associations between particular forms of immunodeficiency and particular infections, and some of these are listed in Table 5 . References: ECHO-virus infections (Wilfert et al., 1977) ; pneumocystis infection (Hughes et al., 1975) ; Neisseria infections (Lancet, 1978) .
The lack of a spleen has been studied in some detail. Apparently there is deficient antibody production in the primary response and a failure to transfer from IgM to IgG antibody formation after repeated antigenic stimulation (Sullivan et al., 1978) . In general the pattern of immune reactions is so complex, with H. E. M. Kay interactions between the different cell populations and compensating mechanisms to remedy any single defect, that we should regard any degree or mode of suppression as a predisposition to any sort of infection. What, in brief, can be done (Table 6) ? Obviously isolation and hygiene can be invaluable in preventing primary infections. A few simple inexpensive measures such as the use of a side-ward and handwashing can give some protection to a patient with myelosuppression-for example, acute myeloid leukaemia-for the time that he requires it. Avoidance of the main sources of respiratory pathogens should be attempted, especially for children with acute lymphatic leukaemia, but where contact occurs passive immunisation is needed. Ideally, perhaps, imminoglobulin could be given routinely if there were adequate supplies. There is a place for active immunisation, especially with pneumococcal vaccines (Lancet, 1978) , and perhaps with other organisms if the killed vaccines are effective. Antibiotic prophylaxis is certainly worthwhile in some circumstances-penicillin to guard against pneumococcal infection, co-trimoxazole for Pneumocystis infection, and a non-absorbable antibiotic regimen during short periods of neutropenia as in acute myeloid leukaemia.
Of the greatest practical importance is the diagnosis of infections in the immunosuppressed patient. This may be a difficult matter for reasons given in Table 7 . The usual signs of infection may be absent and for similar reasons diagnostic tests may fail. On the other hand, the organisms may be unusually prolific and in the long run antibodyproduction seldom fails completely except in congenital states. Inaccessibility of organisms, the doubtful significance of low-grade pathogens, and multiple infections all help to compound the problems. When it comes to treatment ( Immunoglobulin is often given-for example, for varicella-but is of doubtful benefit, and the introduction of an antibody bolus could precipitate an Arthus-type reaction. Probably this is only a theoretical risk. I know of no actual evidence that giving immunoglobulins is harmful.
Granulocytes are obviously useful whenever neutropenia is severe. They are especially valuable for local infection-for example, a perianal abscess or pneumonia-while platelets may often have to be given in large quantities since they may be consumed in areas of cell damage and inflammation. Remarkable results have been claimed for transfer factor in rare cases of some congenital immunodeficiencies (Kohler et al., 1974) or congenital CMV infection (Thomas et al., 1977) , while interferon has still to be tried on a scale that will allow its evaluation.
